Immunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board
/PRNewswire/ -- Immunis Inc., a private biotechnology company developing an immunomodulatory secretome for age and disease-related immune decline in Phase 1/2a...
Source: prnewswire.com